SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-20-286956
Filing Date
2020-11-05
Accepted
2020-11-05 16:56:29
Documents
10

Document Format Files

Seq Description Document Type Size
1 S-3 d30760ds3.htm S-3 451308
2 EX-1.2 d30760dex12.htm EX-1.2 243693
3 EX-4.5 d30760dex45.htm EX-4.5 286582
4 EX-4.7 d30760dex47.htm EX-4.7 95662
5 EX-4.8 d30760dex48.htm EX-4.8 91400
6 EX-4.9 d30760dex49.htm EX-4.9 90533
7 EX-5.1 d30760dex51.htm EX-5.1 27500
8 EX-23.1 d30760dex231.htm EX-23.1 1593
9 GRAPHIC g30760g1105115910479.jpg GRAPHIC 2532
10 GRAPHIC g30760g71p99.jpg GRAPHIC 50472
  Complete submission text file 0001193125-20-286956.txt   1362587
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-249881 | Film No.: 201291340
SIC: 2836 Biological Products, (No Diagnostic Substances)